Completed PHASE2 INTERVENTIONAL 1-arm NCT00134784

Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression (ELLDOPA)

[123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's Disease

Sponsor: Institute for Neurodegenerative Disorders

Conditions Parkinson Disease

Interventions [123I]B-CIT SPECT imaging

Updated 6 times since 2017 Last updated: Jul 15, 2014 Started: Apr 30, 2000 Primary completion: May 31, 2007 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Parkinson Disease and is currently completed. Institute for Neurodegenerative Disorders leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute for Neurodegenerative Disorders
United States Department of Defense

Data source: Institute for Neurodegenerative Disorders

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.